Healthcare Solutions in Emerging Markets

At Lupin, our purpose to catalyze treatments that transform hope into healing finds strong expression in the work we do across emerging markets in Africa, Asia and Latin America.

Emerging pharma markets are growing at an immense pace due to rising healthcare needs, supportive policies, and an expanding middle-class population. However, widespread access to high-quality, effective medicines remains a challenge in these markets.

Our strategy of expanding access, enhancing impact and fostering resilience with a foundation in excellence and patient-centric care has led these markets to contribute effectively to our global sales, reflecting an on-growing stronghold we have through localized offerings and public health partnerships.

MARKETS

Our businesses across emerging markets, including South Africa, Brazil, Mexico, and the Philippines, are integral to our global expansion and influencing patient care. These dynamic markets demand affordable, effective, and high-quality treatments. The focus on generic drug manufacturing to create high accessibility at lower costs reflects volume growth, market-specific strategies, and efficient cost structures.

South Africa

South Africa is one of our most promising emerging markets, a nation where easy access to affordable and quality healthcare remains imperative. The region hosts a diverse portfolio with a plethora of therapy areas, including cardiac care, diabetes, CNS, and women’s health, to name a few.

Our subsidiary, Pharma Dynamics, is a leading provider of generics and the largest supplier of heart medication in South Africa. Today, we host a broad portfolio of products that consistently rank among the top in key therapy areas, while our OTC franchise also demonstrates strong market leadership.

Through plans of active expansion in the coming years, the South African market is one of the canvases where our purpose comes alive.

Know more about South Africa market

Brazil

MedQuímica, our subsidiary in Brazil, develops various solid and liquid medications that include OTC, branded generics, hospital medications, and food supplements. Certified by the Brazilian Health Regulatory Agency, MedQuímica has penetrated the Brazilian pharma market and impacted millions of lives through affordable and highly accessible medicines.

Know more about Brazil market

Mexico

Our subsidiary Laboratories Grin continues to play a vital role in Mexico, showcasing steady growth, making it one of the top pharma companies in Latin America.

Laboratories Grin is leading the way with its strong presence in the Ophthalmology segment.

As we move forward, Laboratories Grin aims to reinforce its position in the Ophthalmology segment by expanding into adjacent therapies to reach a broader audience. We are deepening our innovative capabilities and local insights to offer accessible care to our patients.

Know more about Mexico market

Philippines

Our subsidiary in the Philippines, Multicare Pharmaceuticals, aims to diversify our portfolio, scale operations, and elevate healthcare standards. We are the leading Indian pharmaceutical company in the Philippines and rank among the top in the branded generics segment. We deliver a vast portfolio of products across therapeutic areas, including women's health, oncology, CNS, anti-diabetes, gastroenterology, respiratory, and anti-TB.

Multicare Pharmaceuticals not only believes in developing high-quality medication but also demonstrates holistic patient care through its patient access programs, offering free consultation to 15,000+ patients.

Know more about the Philippines market

India

India’s pharmaceutical landscape is undergoing rapid transformation, fueled by demographic shifts, an increase in chronic and lifestyle-related diseases, and growing expectations for better healthcare solutions. This momentum has intensified the focus on patient-centric approaches, localized innovation, and integrated care, making India one of the most dynamic and promising pharma markets globally.

Within this environment, our India Region Formulations (IRF) business has emerged as a strong growth engine, consistently outperforming the market. Ranked 8th in the Indian Pharmaceutical Market, IRF is driven by its core therapies- cardiology, respiratory, anti-diabetes, and gastroenterology.

Know more about India market

Middle East and North Africa (MENA)

The MENA pharmaceutical market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic diseases, rising healthcare expenditures and government initiatives aimed at localizing manufacturing and improving healthcare access. The MENA generic pharmaceutical market is dominated by local companies, while Indian companies have a low share. Key opportunities for pharmaceutical companies in the MENA region include government investment, market expansion, digital transformation, innovation and research. These factors position MENA as a promising market for growth from a future perspective.

We are entering strategic collaborations and partnerships with leading local companies in the MENA region. We at Lupin, with our wide product portfolio and R&D capabilities, are committed to providing affordable access to high-quality medicines to patients across the MENA region.

GLOBAL INSTITUTIONAL BUSINESS(GIB)

We at Lupin are dedicated to patient communities, and our Global Institutional Business (GIB) is a testament to this commitment. We work closely with public health institutions and regulatory bodies across more than 50 countries in Africa, Latin America, CIS (Commonwealth of Independent States) and Asia, in a bid to deliver affordable and accessible solutions to battle diseases such as TB and HIV.

We are the world’s largest supplier of first-line anti-TB medicines. Our proven capability in fermentation technology enables the manufacture of Rifa-based products including Rifampicin, Rifapentine, and Rifabutin.
Our regulatory reach across the globe has ensured in-country registrations of anti-TB and HIV drugs across all high-burden countries in Africa, Asia, LATAM and CIS.
We are the first company globally to receive WHO approval for Rifapentine 150 mg dispersible tablets, a pediatric formulation for TB prevention.
We have large installed production capacities to meet the global requirements of anti-TB and HIV drugs.
Our API and formulation facilities have approvals from various regulatory authorities across the globe, including WHOPQ, USFDA, CDSCO, SAHPRA, etc.

With our scale, robust capabilities, and a commitment to help those who need care the most, we, through GIB, reaffirm our commitment to a TB-free world, while continuing to address other high-burden diseases in underserved communities.